Lili Shen, Jinfei Chen, D.y. Gu

Department of Oncology, Nanjing First Hospital, Nanjing Medical University

Objective:we performed this meta-analysis to summarize the effect of H63D variant on solid tumor incidence. Method: The PubMed and EMBASE databases were searched regarding the HFE H63D polymorphism associated with cancer risk. The relationships were evaluated by calculating the pooled odds ratios (ORs) with 95% confidence intervals (CIs). Result: A total of 28 studies including 7,728 cancer cases and 11,895 controls were identified. Statistically significant associations between the HFE H63D polymorphism and solid cancer risk were determined (CG vs. CC, OR=1.14, 95% CI=1.07-1.23, P<0.001; GG vs. CC, OR=1.28, 95% CI=1.06-1.55, P=0.010; CG/GG vs. CC, OR=1.16, 95%CI=1.08-1.24, P<0.001; GG vs. CC/CG, OR=1.24, 95% CI=1.02-1.49, P=0.027). In the subgroup analysis, we illustrated the effect of the H63D polymorphism on hepatocellular carcinoma and pancreatic cancer risk, particularly in Asian and African subgroups, but not on gynecologic malignant tumors. Conclusion: In summary, this analysis provided strong evidence that the HFE H63D polymorphism may play a critical role in the increased aggressiveness of hepatocellular carcinoma and pancreatic cancer.

Key Words: HFE H63D  polymorphism  solid cancer  Molecular